Larimar Therapeutics, Inc.

NASDAQ:LRMR

Biotechnology

Healthcare
$3.23 +0.99%

+$0.04 today

Market cap
$337.45M
Beta
0.82
P/E (TTM)
-1.8
EPS (TTM)
-$1.95
52W Low $2.22High $6.42

Volume 1.41M

Average 1.73M

LRMR Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Larimar Therapeutics, Inc.NASDAQ: LRMR

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow outflow grows to $108.12M

Q1 FY2026 financing cash flow was $108.12M, compared with $0 a year earlier. Trailing-twelve-month financing cash flow was $173.2M. Over 3 fiscal years it compounded at -4.7% a year.

Context

  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly financing cash flow holds near $108.12M or moves back toward the trailing-twelve-month quarterly average of $43.3M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$108.12M+53888.6% QoQ
Last fiscal yearDec 2025
$65.09M-59.8% YoY
LTMMar 2026
$173.2M+64727.2% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-59.8%——
3-year CAGR-4.7%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
65.09M USD
Year-over-year change
-59.8%
4-year CAGR
+34.5%

Financing Cash Flow vs competitors

How LRMR compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +64727.2% is the 2nd highest of 11, against a peer median of +301.5%.
  • Over three fiscal years its annual growth of -4.7% compares with a peer median of +33.2%.
LRMR Competitors
Financing Cash Flow for LRMR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DBVTDBV Technologies S.A.LTM Mar 2026$365.04M USD+52499.0%+12.5%—
ALTAltimmune, Inc.LTM Mar 2026$251.49M USD+466.1%+53.9%698594.4%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$219.24M USD+164739.1%+946.8%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$173.2M USD+64727.2%-4.7%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$165.89M USD+1517.0%+11.1%—
ENGNenGene Holdings Inc.LTM Apr 2026$143.06M USD+136.8%-62.1%—
ANNXAnnexon, Inc.LTM Mar 2026$141.69M USD+10.0%-4.0%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$141.48M USD+10580.1%+128.2%—
KRROKorro Bio, Inc.LTM Mar 2026$88.73M USD+27.9%+236.4%2309.3%
AMRNAmarin Corporation plcLTM Mar 2026$2.59M USD+127.8%+75.3%1.2%
ACIUAC Immune S.A.LTM Dec 2025CHF 1.02M CHF-9.0%-10.2%28.5%
Peer median (excluding LRMR) —+301.5%+33.2%1168.9%

Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(50.64M)(35.36M)(36.95M)(80.6M)(165.67M)
Depreciation & Amortization326K318K311K318K(1.35M)
Deferred Income Tax00000
Stock-Based Compensation5.47M6.62M7.62M8.8M7M
Change in Working Capital2.75M1.67M(2.51M)6.18M47.1M
Accounts Receivables00000
Inventory00000
Accounts Payables(974K)26K(403K)1.14M2.79M
Other Working Capital3.72M1.64M(2.11M)5.03M44.31M
Other Non-Cash Items(15K)(820K)(1.93M)(5.45M)(281K)
Operating Cash Flow(42.11M)(27.57M)(33.46M)(70.76M)(113.2M)
Capital Expenditures(333K)(100K)(164K)(515K)(91K)
Acquisitions (Net)(24.5K)90.86K000
Purchases of Investments(8.25M)(133.61M)(101.23M)(227.87M)(83.6M)
Sales of Investments32.75M42.75M134.75M143M184M
Other Investing Activities24.5K(90.86K)000
Investing Cash Flow24.17M(90.96M)33.35M(85.39M)100.31M
Debt Repayment00000
Common Stock Issued19.89M75.26M30K161.81M65.09M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00077K0
Financing Cash Flow19.89M75.26M30K161.88M65.09M
Effect of Forex Changes00000
Net Change in Cash1.95M(43.27M)(76K)5.74M52.19M
Free Cash Flow(42.44M)(27.67M)(33.62M)(71.28M)(113.29M)

Larimar Therapeutics, Inc.

NASDAQ:LRMR

Intrinsic Alpha fair value

Locked

Current Price

$3.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.